Goldman Sachs’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-20,000
| Closed | -$1.7M | – | 5760 |
|
|
2019
Q4 | $1.7M | Buy |
+20,000
| New | +$1.33M | ﹤0.01% | 3763 |
|
|
2019
Q1 | – | Sell |
-15,000
| Closed | -$287K | – | 5601 |
|
|
2018
Q4 | $287K | Hold |
15,000
| – | – | ﹤0.01% | 4657 |
|
|
2018
Q3 | $449K | Hold |
15,000
| – | – | ﹤0.01% | 4485 |
|
|
2018
Q2 | $551K | Hold |
15,000
| – | – | ﹤0.01% | 4453 |
|
|
2018
Q1 | $494K | Sell |
15,000
-189,200
| -93% | -$5.91M | ﹤0.01% | 4497 |
|
|
2017
Q4 | $5.58M | Buy |
204,200
+100,000
| +96% | +$3.08M | ﹤0.01% | 2924 |
|
|
2017
Q3 | $3.86M | Sell |
104,200
-126,000
| -55% | -$4.64M | ﹤0.01% | 3396 |
|
|
2017
Q2 | $8.75M | Buy |
230,200
+81,000
| +54% | +$3.61M | ﹤0.01% | 2611 |
|
|
2017
Q1 | $7.3M | Buy |
+149,200
| New | +$6.8M | ﹤0.01% | 2625 |
|
|
2016
Q2 | – | Sell |
-3,400
| Closed | -$108K | – | 7375 |
|
|
2016
Q1 | $108K | Sell |
3,400
-68,800
| -95% | -$2.25M | ﹤0.01% | 6043 |
|
|
2015
Q4 | $2.7M | Sell |
72,200
-227,000
| -76% | -$8.58M | ﹤0.01% | 3371 |
|
|
2015
Q3 | $11.4M | Sell |
299,200
-200
| -0.1% | -$7.02K | ﹤0.01% | 2156 |
|
|
2015
Q2 | $8.57M | Buy |
299,400
+105,000
| +54% | +$2.92M | ﹤0.01% | 2465 |
|
|
2015
Q1 | $5.45M | Buy |
+194,400
| New | +$5.46M | ﹤0.01% | 2806 |
|
|
2014
Q3 | – | Sell |
-197,100
| Closed | -$5.73M | – | 7344 |
|
|
2014
Q2 | $5.73M | Sell |
197,100
-44,500
| -18% | -$1.19M | ﹤0.01% | 2888 |
|
|
2014
Q1 | $6.87M | Buy |
241,600
+180,700
| +297% | +$5.98M | ﹤0.01% | 2696 |
|
|
2013
Q4 | $2.35M | Buy |
+60,900
| New | +$2.18M | ﹤0.01% | 3906 |
|
Other funds holding MDCO
Goldman Sachs's MDCO Position: Q1 2020 in Review
Goldman Sachs sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 986,518 shares — an estimated $83.8M sold.
Goldman Sachs first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $113M in Q3 2017. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Goldman Sachs reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Goldman Sachs sold 986,518 Medicines Co shares in Q1 2020, an estimated $83.8M.
- Goldman Sachs first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
- Goldman Sachs's Medicines Co position peaked at $113M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Goldman Sachs's 13F filing for Q1 2020, filed 15 May 2020.